Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

15000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-30

Study Completion Date

2035-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Registry of Multiplex Testing (PROMPT)

NCT02665195

Genetic Testing

ACTIVE_NOT_RECRUITING

Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

NCT01498250

Basal Cell Carcinoma

COMPLETED

Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation

NCT02412579

Hepatocellular Carcinoma

COMPLETED

Biomarker Monitoring in TP53 Mutation Carriers

NCT02289326

Li-Fraumeni Syndrome Hereditary Cancer Syndromes TP53 Gene Germline Mutation Carrier

COMPLETED

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

NCT06489041

Cancer Gastrointestinal Cancer

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators have identified germ-line microRNA binding site mutations that predict an increased risk of cancer, endometriosis and associated infertility, and unique tumor biology and response to treatment. The goal of this protocol is to further determine the mechanisms of these mutations, such as the KRAS-variant, and their associations with human health, such as cancer. The investigators will collect saliva samples from individual patients who are eligible and choose to enroll in these studies, to test for the KRAS-variant and/or other mutations under study. With specific permission, the investigators will keep excess DNA to further investigate and discover additional similar mutations. The investigators purpose is to have participants answer questionnaires about lifestyle factors in an ongoing manner, to understand the impact of different factors on cancer risk for patients with these mutations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Family Registry

For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.